MGV
US ValueVanguard Mega Cap Value Index Fund
Vanguard · Tracks CRSP US Mega Cap Value Index · Inception Mar 5, 2008
Composite score
Based on a 0.050% expense ratio.
Based on $13.31B in net assets.
Top-10 holdings represent 26.7% of net assets.
US Value base · ETF wrapper · 1.88% TTM yield.
The composite is a weighted average of the four core sub-scores above (cost, tax efficiency, liquidity, concentration). Missing sub-scores fall back to the per-category median when the category has at least 50% data coverage, so funds without (e.g.) parsed N-PORT holdings aren't accidentally boosted by renormalization. Tracking quality is shown where computable but isn't currently part of the composite weighting. See methodology for formulas, the tracking-quality partial-coverage rationale, and the dimensions we deliberately don't score (methodology v0.5.1).
Use MGV in our tools
Tool · Cost
Compare MGV's fee against another fund
Compounds the 0.050% expense ratio against a peer over decades.
Tool · Overlap
Compare MGV's holdings with peers
Pairwise holdings heatmap, pre-loaded with similar US Value funds.
Tool · TLH
Find a tax-loss harvesting partner for MGV
Ranks every catalog fund by holdings overlap, flags wash-sale risk.
Tool · Placement
Where should this fund live across your accounts?
Asset-location optimizer — places each fund in taxable / tax-deferred / Roth.
Top holdings
| # | Holding | Weight |
|---|---|---|
| 1 | JPMorgan Chase & Co | 3.83% |
| 2 | Berkshire Hathaway Inc | 3.47% |
| 3 | Exxon Mobil Corp | 3.21% |
| 4 | Johnson & Johnson | 2.99% |
| 5 | Walmart Inc | 2.80% |
| 6 | Micron Technology Inc | 2.32% |
| 7 | Costco Wholesale Corp | 2.24% |
| 8 | AbbVie Inc | 2.05% |
| 9 | Procter & Gamble Co/The | 1.95% |
| 10 | Home Depot Inc/The | 1.89% |
Compare MGV with another fund
Or skim the closest-overlap funds below.
Similar ETFs by holdings overlap
Open MGV at a brokerage
Affiliate links — opening an account through these earns PlainIndex a one-time referral. Scoring is computed before any affiliate consideration; see our methodology and funding disclosure.